Search by Drug Name or NDC

    NDC 63102-0104-16 ACTINEL DM 20; 400; 10 mg/5mL; mg/5mL; mg/5mL Details

    ACTINEL DM 20; 400; 10 mg/5mL; mg/5mL; mg/5mL

    ACTINEL DM is a ORAL SOLUTION in the HUMAN OTC DRUG category. It is labeled and distributed by Actipharma, Inc. The primary component is DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE.

    Product Information

    NDC 63102-0104
    Product ID 63102-104_7ee7ae4e-b359-4c71-8cd6-d12ed54e5158
    Associated GPIs 43997303100980
    GCN Sequence Number 066799
    GCN Sequence Number Description guaifen/dextromethorphan/PE LIQUID 400-20-10 ORAL
    HIC3 B4R
    HIC3 Description NON-OPIOID ANTITUSSIVE-DECONGESTANT-EXPECTORANT
    GCN 29196
    HICL Sequence Number 000216
    HICL Sequence Number Description GUAIFENESIN/DEXTROMETHORPHAN HBR/PHENYLEPHRINE
    Brand/Generic Generic
    Proprietary Name ACTINEL DM
    Proprietary Name Suffix n/a
    Non-Proprietary Name Dextromethorphan HBr, Guaifenesin, Phenylephrine HCl
    Product Type HUMAN OTC DRUG
    Dosage Form SOLUTION
    Route ORAL
    Active Ingredient Strength 20; 400; 10
    Active Ingredient Units mg/5mL; mg/5mL; mg/5mL
    Substance Name DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE
    Labeler Name Actipharma, Inc
    Pharmaceutical Class Adrenergic alpha1-Agonists [MoA], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]
    DEA Schedule n/a
    Marketing Category OTC MONOGRAPH FINAL
    Application Number part341
    Listing Certified Through 2024-12-31

    Package

    NDC 63102-0104-16 (63102010416)

    NDC Package Code 63102-104-16
    Billing NDC 63102010416
    Package 474 mL in 1 BOTTLE, PLASTIC (63102-104-16)
    Marketing Start Date 2019-05-20
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL 16660d82-524b-42ca-8581-48237caa13b2 Details

    Revised: 5/2019